clinical trial · NCT07529925
A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·phase4·not yet recruiting·n = 30
Severe Plaque Psoriasis in Chinese ChildrenAdalimumab Solution for Injection
brief summary
This study is a real-world clinical study of adalimumab. The project plans to enrol 30 participants and aims to evaluate the efficacy and safety of adalimumab in Chinese children with plaque psoriasis, with the primary endpoint being the proportion of participants achieving PASI 75 (PASI score reduction ≥75% from baseline) at week 16.
started
May 1, 2026
primary completion
Apr 1, 2028
completion
May 1, 2028
last updated
Apr 14, 2026
official title
A Multicenter, Open-label Study on the Efficacy and Safety of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol